All IndicationsRare & Genetic DiseasesPhase 3Phase 3Phase 3Phase 3Phase 2Phase 2
🧬
Duchenne Muscular Dystrophy
6
Companies
10
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
CAPR
Capricor Therapeutics, Inc.
CAP-1002
Fast TrackOrphan Drug
SRPT
Sarepta Therapeutics, Inc.
Eteplirsen
SRPT
Sarepta Therapeutics, Inc.
SRP-4045
RHHBY
Roche Holding AG
RO7239361
SRPT
Sarepta Therapeutics, Inc.
Placebo
SRPT
Sarepta Therapeutics, Inc.
AVI-4658 for Injection
CAPC
Capricor Therapeutics
deramiocel
PDUFA: Aug 2026
BMY
Bristol Myers
Capricor Duchenne cell therapy
RGNX
REGENXBIO
RGX-202
CAPR
Capricor Therapeutics
deramiocel
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| CAPR Capricor Therapeutics, Inc. | CAP-1002 | Phase 3 | FTOD | — | — |
| SRPT Sarepta Therapeutics, Inc. | Eteplirsen | Phase 3 | — | — | — |
| SRPT Sarepta Therapeutics, Inc. | SRP-4045 | Phase 3 | — | — | — |
| RHHBY Roche Holding AG | RO7239361 | Phase 3 | — | — | — |
| SRPT Sarepta Therapeutics, Inc. | Placebo | Phase 2 | — | — | — |
| SRPT Sarepta Therapeutics, Inc. | AVI-4658 for Injection | Phase 2 | — | — | — |
| CAPC Capricor Therapeutics | deramiocel | — | — | Aug 2026 | — |
| BMY Bristol Myers | Capricor Duchenne cell therapy | — | — | — | — |
| RGNX REGENXBIO | RGX-202 | — | — | — | — |
| CAPR Capricor Therapeutics | deramiocel | — | — | — | — |
Development Stage Distribution
Unknown
4
Phase 3
4
Phase 2
2
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.